Liquidia Court & Legal Update
Liquidia Corporation entered into a global settlement agreement with United Therapeutics to resolve all ongoing patent infringement, trade secret, and antitrust litigation. Liquidia will make aggregate payments of $320.4 million to UTC ($175M net initial payment plus $145.4M in 2027 installments) while agreeing to remove the PH-ILD indication from its YUTREPIA label to maintain the product's availability for PAH patients.
- Counterparty
- United Therapeutics Corporation
“Today’s agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA, whose differentiated attributes have enabled its rapid adoption by physicians and patients since launch.”
Dr. Roger Jeffs, CEO